7. THE PROBLEM
Well plate technology has not changed
in over 50 years
This 50 year-old technology is inefficient and comes with high
capital costs
Complicated workflows
Need large testing volumes (loss of reagents)
Unstable (greater room for errors)
7
9. CURRENT SOLUTIONS ARE INADEQUATE
Costly Capex (smaller companies cannot afford the current
technology)
Not scalable
Cannot handle high testing volumes
High margin for errors
Competitors believe these obstacles are just part of doing business.
Neofluidics knows better, and we deliver on that knowledge by
providing more efficient workflows through engineering-driven
technology.
9
11. Reduced
sample volumes
= 99% cost
savings!
Our lab-on-a-chip technology is in position to change the future of the field of drug discovery.
THE NEOFLUIDICS SOLUTION
No Capex
(affordable for
all companies,
large and small)
Compatibility
with existing
equipment
Error-free
pipetting
control
Enhanced
quality of
testing
Ease of
dilution
On-site testing Fast results
13. A NEW PLATFORM FOR SCREENING TECHNOLOGY
Neofluidics products bring unprecedented efficiency to many different
types of screening workflows by offering the following benefits:
Drastically reduces the volume needed to test
compounds, not only allowing more tests to be run with
rare compounds, such as with those from plant-derived
sources that are available in extremely limited
quantities, but also reducing reagent costs by up to 99%.
Does not require additional Capex, which enables
smaller companies with limited budgets to undertake
large-scale drug screening campaigns.
The simplicity and small footprint of the technology
facilitates point of care diagnostics, increasing
sensitivity of typical ELISA based screening.
13
14. A NEW PLATFORM FOR SCREENING TECHNOLOGY
Can screen small animal models (such as
C.elegans and Zebrafish) in a high throughput
fashion.
Can perform single-cell analysis with a series
of microfluidic trapping chambers designed to
capture single cells from a larger initial
population.
Can facilitate cell culture and tissue organ
modeling to test drug toxicity.
14
Zebrafish
16. THE MARKET
New market research1 on the High Throughput Screening
Market by Technology, Applications, and End Users:
R&D costs to discover a single drug
have risen to $2.9-9 billion USD.2
In the past 50 years, the money
spent on drug discovery has
increased by 674%.
The primary screening segment of
drug discovery is poised to grow at
the highest compound annual
growth rates in the industry.
$13.7
2013 Current global
HTS screening market
Billion
$19.6
Billion
2018 (Projected
CAGR of 7.4%)
16
17. THE MARKET
17
1 www.marketsandmarkets.com
2
Diagnosing the decline in pharmaceutical
R&D efficiency, Jack W. Scannell, Alex
Blanckley, Helen Boldon & Brian
Warrington,
Nature Reviews Drug Discovery 11,
191-200 (March 2012)
18. THE NEOFLUIDICS STORY
Delivering on technology.
Neofluidics was born out of a doctoral thesis and has since disrupted a
microfluidics product category that hasn’t changed in fifty years.
We challenge prevailing assumptions in fluid mechanics regarding
complicated workflows, pipetting errors, and high screening costs.
Neofluidics develops next-generation tools and technology not only for the
bioscience sector, but also in the military and petroleum sectors for enhanced
microfluidics.
Our engineering-driven products add unprecedented convenience and
efficiency to workflows, significantly reducing the costs of testing, culture,
measurement, and analysis.
18
20. MARKET OPPORTUNITY
Audiences
Lab Screening
Technicians
Single-Cell Genomics
and Cancer Research
Scientists
Point-of-Care
Diagnostics Providers
Pharmaceutical
Scientists
Pharmaceutical
Screening
Drug Screening
Cosmetic Screening
Pharmaceutical
Research and
Development
Academic Research
and Development
Equine Banned
Substance Testing
Sports Banned
Substance Testing
Protein Solution
Viscosity
Characterization
20
21. MARKET OPPORTUNITY
Petroleum Engineers Military
Drilling Fluid
Analysis
In-line Viscosity
Measuring For
Hydraulic Fluids and
Fuel Condition
Future Target Audiences
21
28. MEET OUR TEAM
Dr. Deepak
Solomon
Chief Product
Engineer
Dr. Nilesh
Gupta
Chief Scientific
Officer
Dr. Kevin
Crawford
Chief Operating
Officer
Charles E.
Needham
Chief Marketing
Officer
Alpesh
Indulkar
Chief
Manufacturing
Officer
Dr. Rathnam
Chagturu
Director of HTS at
Stanford Research
International (SRI)
Dr. Ali
Khadim
Hosseini
Professor, MIT
Dr. Barbara
Smith
Professor, ASU
28
